Talk:Embolic and thrombotic events after COVID-19 vaccination: Difference between revisions
Content deleted Content added
→Requested move 18 December 2021: responses to comments |
|||
Line 55:
* [https://www.thrombosisresearch.com/article/S0049-3848(21)00479-5/fulltext This ''Thrombosis Research'' article] discusses the names:<blockquote>We believe the name “VITT” works well, for two reasons. First, the term clearly denotes the key features of the disorder, and the sequence of letters provides a useful mnemonic for disease recognition in the usual sequence of events: … Second, the term “VITT” itself need not mandate that thrombosis be present … Another term used in the United States … “TTS” … highlights the two key clinical features of thrombosis and thrombocytopenia but without denoting either preceding vaccination or alluding to its immune-mediated pathogenesis. This term has limited clinical utility, since many conditions … present with the duad of thrombosis and thrombocytopenia</blockquote>
* [https://www.thelancet.com/journals/lanhae/home The Lancet Haematology] says: <blockquote>Although initially several terms were used to describe the syndrome, such as vaccine-associated thrombosis with thrombocytopenia and vaccine-induced prothrombotic immune thrombocytopenia, the term that has gained widespread use is vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombosis with thrombocytopenia syndrome has also been used, but it is a more general term that can be caused by other conditions, such as antiphospholipid syndrome and thrombotic thrombocytopenic purpura.</blockquote>
* UpToDate has a summary of the latest information: [https://www.uptodate.com/contents/covid-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)] <blockquote>VITT antibodies bind to platelets via an eight amino acid region of PF4 on the platelet surface, located within the heparin binding site [4]. VITT antibody binding is blocked by heparin. The amino acids bound by VITT antibodies overlap with but differ from the amino acids bound by HIT antibodies, and VITT antibody binding to platelets is stronger than HIT antibody binding. … Other adenoviral vaccines have been administered to large numbers of individuals without reported cases of VITT. Examples include Ad5-based COVID-19 vaccine (CanSino Biologics), Gam-COVID-Vac/Sputnik V (Gamaleya Institute), and Ad26.ZEBOV-GP (recombinant) Ebola vaccine (Janssen Biologics).</blockquote>
— [[User:Omegatron|Omegatron]] ([[User talk:Omegatron|talk]]) 16:40, 18 December 2021 (UTC)
| |||